{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:29:16Z","timestamp":1773408556142,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,5,18]],"date-time":"2010-05-18T00:00:00Z","timestamp":1274140800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s10147-010-0094-1","type":"journal-article","created":{"date-parts":[[2010,5,17]],"date-time":"2010-05-17T02:32:32Z","timestamp":1274063552000},"page":"468-471","source":"Crossref","is-referenced-by-count":20,"title":["Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer"],"prefix":"10.1007","volume":"15","author":[{"given":"Yoh","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomaro","family":"Etoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Koike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Hoshiai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,5,18]]},"reference":[{"key":"94_CR1","doi-asserted-by":"crossref","unstructured":"Pujade-Lauraine S, Mahner S, Kaern J et al (2009) A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CARYPSO study of the Gynecologic Cancer Intergroup (GCIG). J Clin Oncol 27:18s (suppl; abstr LBA5509)","DOI":"10.1200\/jco.2009.27.18s.lba5509"},{"key":"94_CR2","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/annonc\/mdi147","volume":"16","author":"AJ Gonzalez-Martin","year":"2005","unstructured":"Gonzalez-Martin AJ, Calvo E, Bover I et al (2005) Randomized phase II trial of carboplatin versus paclitaxel carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Onvestigation en Cancer de Ovario) study. Ann Oncol 16:749\u2013755","journal-title":"Ann Oncol"},{"key":"94_CR3","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","volume":"361","author":"MK Parmer","year":"2003","unstructured":"Parmer MK, Ledermann JA, Colombo N et al (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial. Lancet 361:2099\u20132106","journal-title":"Lancet"},{"key":"94_CR4","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","volume":"25","author":"DG Mutch","year":"2007","unstructured":"Mutch DG, Orlando M, Goss T et al (2007) Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25:2811\u20132818","journal-title":"J Clin Oncol"},{"key":"94_CR5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/annonc\/mdh025","volume":"15","author":"W ten Bokkel Huinink","year":"2004","unstructured":"ten Bokkel Huinink W, Lane SR, Ross GA (2004) Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 15:100\u2013103","journal-title":"Ann Oncol"},{"key":"94_CR6","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"AN Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT, Guthrie D et al (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312\u20133322","journal-title":"J Clin Oncol"},{"key":"94_CR7","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10147-008-0765-3","volume":"13","author":"Y Watanabe","year":"2008","unstructured":"Watanabe Y, Koike E, Nakai H et al (2008) Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer. Int J Clin Oncol 13:345\u2013348","journal-title":"Int J Clin Oncol"},{"key":"94_CR8","unstructured":"National Comprehensive Cancer Network (NCCN) Practice Guidelines in Oncology-v.2.2009. http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/ovarain.pdf"},{"key":"94_CR9","unstructured":"Southwest Oncology Group Statistical Center. http:\/\/www.swogstat.org\/stat\/public\/one_binomial.htm"},{"key":"94_CR10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"94_CR11","unstructured":"Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http:\/\/ctep.cancer.gov"},{"key":"94_CR12","unstructured":"Japan Society of Gynecologic Oncology Ovarian cancer treatment guidelines 2007 (in Japanese). KANEHARA & Co., Ltd., Tokyo"},{"key":"94_CR13","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1200\/JCO.2007.15.1258","volume":"26","author":"J Sehouli","year":"2008","unstructured":"Sehouli J, Stengel D, Oskay-Oezcelik G et al (2008) Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 26:3176\u20133182","journal-title":"J Clin Oncol"},{"key":"94_CR14","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2007.13.6606","volume":"26","author":"G Ferrandina","year":"2008","unstructured":"Ferrandina G, Ludovici M, Lorusso D et al (2008) Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 26:890\u2013896","journal-title":"J Clin Oncol"},{"key":"94_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","volume":"95","author":"AN Gordon","year":"2004","unstructured":"Gordon AN, Tonda M, Sun S et al (2004) Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95:1\u20138","journal-title":"Gynecol Oncol"},{"key":"94_CR16","first-page":"358","volume":"26","author":"S Alici","year":"2003","unstructured":"Alici S, Saip P, Eralp Y et al (2003) Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC). Am J Clin Oncol 26:358\u2013362","journal-title":"Am J Clin Oncol"},{"key":"94_CR17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.1998.16.2.405","volume":"16","author":"PG Rose","year":"1998","unstructured":"Rose PG, Blessing JA, Mayer AR et al (1998) Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 16:405\u2013410","journal-title":"J Clin Oncol"},{"key":"94_CR18","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/oxfordjournals.annonc.a058942","volume":"5","author":"R Wit de","year":"1994","unstructured":"de Wit R, van der Burg M, Gaast A et al (1994) Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12\u00a0months after platinum-containing chemotherapy. Ann Oncol 5:656\u2013657","journal-title":"Ann Oncol"},{"key":"94_CR19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/bjc.1994.33","volume":"69","author":"MT Saymour","year":"1994","unstructured":"Saymour MT, Mansi JL, Gallagher CJ et al (1994) Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer 69:191\u2013195","journal-title":"Br J Cancer"},{"key":"94_CR20","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J","volume":"57","author":"G Omura","year":"1986","unstructured":"Omura G, Blessing JA, Ehrlich CE et al (1986) A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer 57:1725\u20131730","journal-title":"Cancer"},{"key":"94_CR21","first-page":"343","volume":"18","author":"RJ Weat","year":"1997","unstructured":"Weat RJ, Zweig SF (1997) Meta-analysis of chemotherapy regimens for ovarian carcinoma: a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide. Eur J Gyneacol Oncol 18:343\u2013348","journal-title":"Eur J Gyneacol Oncol"},{"key":"94_CR22","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","volume":"92","author":"MJ Piccart","year":"2000","unstructured":"Piccart MJ, Bertelsen K, James K et al (2000) Randomized intergroup trial of cisplatin\u2013paclitaxel versus cisplatin\u2013cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92:699\u2013708","journal-title":"J Natl Cancer Inst"},{"key":"94_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"334","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, Hoskins WJ, Brady MF et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1\u20136","journal-title":"N Engl J Med"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-010-0094-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-010-0094-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-010-0094-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T16:23:28Z","timestamp":1559147008000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-010-0094-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,18]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["94"],"URL":"https:\/\/doi.org\/10.1007\/s10147-010-0094-1","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,18]]}}}